UK Cancer Biomarker Market Size, Share and Forecast 2019-2025
UK cancer biomarker market is expected to grow at a CAGR of around 11.7% during the forecast period. The major factor that are increasing the market are high prevalence of cancer in the region, well-developed healthcare infrastructure and presence of major market player in the nation. Additionally, as the country have developed economy, per capita healthcare investment from government and public is higher than other developing nation and hence significant research can be observed in the near future.
To Request a Sample of our Report on UK Cancer Biomarker Market: https://www.omrglobal.com/request-sample/uk-cancer-biomarker-market
The healthcare expenditure of the UK is more than $25,000 million as
compared to Germany and France. This is one of the major factors that tends to
rise the UK cancer biomarker market. AS per OECD, the prevalence of cancer in
the UK is approx. 225 per 100,000 people in 2011 which is estimated to reduce
only to 214 per 100,000 people in 2017. The incidences of cancer patients in
the UK has been very frequent previously.
The increasing integration of healthcare with technology is augmenting the UK cancer biomarker market. There are various procedures that are being uniquely available at UK treatment centres. For instance, the Clatter Bridge Cancer Centre is one of the first two hospitals in the UK to offer dose painting radiotherapy to patients. The technique is suitable for patients with a higher density of cancer cells, which have not spread from the prostate gland. This applies to 30- 50% of all prostate cancer cases. While an equal amount of radiation is delivered by the standard radiotherapy on prostate, in dose painting radiotherapy, MRI scans or PET CT scans first identify areas of the prostate which is more affected.
Further, during the year 2016/2017 the Cancer Research UK supported the
research based on cancer worth $490.22 million. On the lung cancer research
$55.11 million was spent whereas an amount of $44.06 million was spent in the
research of colon and rectal cancer. For, breast cancer $ 41.65 million was
spent on the research. The funding in the research is expected to motivate the
UK market of cancer biomarker. Thus, such contributions by the government
organizations is expected to further drive the UK cancer biomarker market.
A
full Report of UK Cancer Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/uk-cancer-biomarker-market
UK Cancer
Biomarker Market Segmentation
·
Genetic
Biomarker
·
Protein
Biomarker
By Cancer
Type
·
Lung
Cancer
·
Prostate
Cancer
·
Breast
Cancer
·
Colorectal
Cancer
·
Cervical
Cancer
·
Other
By
Applications
·
Drug
Discovery and Development
·
Diagnosis
·
Risk
Assessment
·
Prognostics
By Profiling
Technology
·
Omics
Technology
·
Immunoassays
·
Cytogenetics
·
Bioinformatics
Company Profiles
·
Abbott
laboratories Inc.
·
Astellas
Pharma Inc.
·
Becton,
Dickson and Co.
·
Bio-Rad
Laboratories, Inc.
·
Danaher
Corp.
·
F.
Hoffmann-La Roche Ltd.
·
Merck
and Co., Inc.
·
Novartis
AG
·
Pfizer
Inc.
·
QIAGEN
GmbH
·
Thermo
Fisher Scientific Inc.
Reasons to Buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/uk-cancer-biomarker-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
For
More Information, Visit Orion Market Research
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment